Hepatic RIG-I predicts survival and interferon-α therapeutic response in hepatocellular carcinoma

Cancer Cell

Volumn 25, Issue 1, 2014, Pages 49-63

  Hou, Jin ^a,b   Zhou, Ye ^a   Zheng, Yuanyuan ^a   Fan, Jia ^c   Zhou, Weiping ^d   Ng, IreneO L ^e   Sun, Huichuan ^c   Qin, Lunxiu ^c   Qiu, Shuangjian ^c   Lee, JoyceM F ^e   Lo, Chung Mau ^e   Man, Kwan ^e   Yang, Yuan ^d   Yang, Yun ^d   Yang, Yingyun ^b   Zhang, Qian ^a,b   Zhu, Xuhui ^a   Li, Nan ^a   Wang, Zhengxin ^f   Ding, Guoshan ^f   Zhuang, Shi Mei ^g   Zheng, Limin ^g   Luo, Xiaoling ^h   Xie, Yuan ^h   Liang, Anmin ^h   Wang, Zhugang ⁱ   Zhang, Ming ⁱ   Xia, Qiang ⁱ   Liang, Tingbo ^j   Yu, Yizhi ^a   Cao, Xuetao ^a,b   more..

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^c ZHONGSHAN HOSPITAL OF FUDAN UNIVERSITY   (China)

^d EASTERN HEPATOBILIARY SURGERY HOSPITAL   (China)

^e THE UNIVERSITY OF HONG KONG   (Hong Kong)

^f SECOND MILITARY MEDICAL UNIVERSITY   (China)

^g SUN YAT SEN UNIVERSITY   (China)

^h GUANGXI MEDICAL UNIVERSITY   (China)

ⁱ SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^j ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; PROTEIN TYROSINE PHOSPHATASE SHP 1; STAT1 PROTEIN;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RETINOIC ACID INDUCIBLE GENE I; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE; YOUNG ADULT;

ADULT; AGED; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; DEAD-BOX RNA HELICASES; DRUG RESISTANCE, NEOPLASM; FEMALE; HETEROGRAFTS; HUMANS; IMMUNOHISTOCHEMISTRY; INTERFERON-ALPHA; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MICE; MICE, NUDE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; SEX CHARACTERISTICS; SIGNAL TRANSDUCTION; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

EID: 84892434546     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2013.11.011     Document Type: Article

References (49)

1. An H., Hou J., Zhou J., Zhao W., Xu H., Zheng Y., Yu Y., Liu S., Cao X. Phosphatase SHP-1 promotes TLR- and RIG-I-activated production of type I interferon by inhibiting the kinase IRAK1. Nat. Immunol. 2008, 9:542-550.
2. Besch R., Poeck H., Hohenauer T., Senft D., Häcker G., Berking C., Hornung V., Endres S., Ruzicka T., Rothenfusser S., Hartmann G. Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon-independent apoptosis in human melanoma cells. J.Clin. Invest. 2009, 119:2399-2411.
3. Buch S.C., Kondragunta V., Branch R.A., Carr B.I. Gender-based outcomes differences in unresectable hepatocellular carcinoma. Hepatol. Int. 2008, 2:95-101.
4. Budhu A., Forgues M., Ye Q.H., Jia H.L., He P., Zanetti K.A., Kammula U.S., Chen Y., Qin L.X., Tang Z.Y., Wang X.W. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 2006, 10:99-111.
5. Chawla-Sarkar M., Lindner D.J., Liu Y.F., Williams B.R., Sen G.C., Silverman R.H., Borden E.C. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 2003, 8:237-249.
6. Chen G., Wang H., Xie S., Ma J., Wang G. STAT1 negatively regulates hepatocellular carcinoma cell proliferation. Oncol. Rep. 2013, 29:2303-2310.
7. Chen W., Han C., Xie B., Hu X., Yu Q., Shi L., Wang Q., Li D., Wang J., Zheng P., et al. Induction of Siglec-G by RNA viruses inhibits the innate immune response by promoting RIG-I degradation. Cell 2013, 152:467-478.
8. Clavien P.A. Interferon: the magic bullet to prevent hepatocellular carcinoma recurrence after resection?. Ann. Surg. 2007, 245:843-845.
9. David M., Chen H.E., Goelz S., Larner A.C., Neel B.G. Differential regulation of the α/β interferon-stimulated Jak/Stat pathway by the SH2 domain-containing tyrosine phosphatase SHPTP1. Mol. Cell. Biol. 1995, 15:7050-7058.
10. de Veer M.J., Holko M., Frevel M., Walker E., Der S., Paranjape J.M., Silverman R.H., Williams B.R. Functional classification of interferon-stimulated genes identified using microarrays. J.Leukoc. Biol. 2001, 69:912-920.
11. Dohmen K., Shigematsu H., Irie K., Ishibashi H. Longer survival in female than male with hepatocellular carcinoma. J.Gastroenterol. Hepatol. 2003, 18:267-272.
12. El-Serag H.B. Hepatocellular carcinoma. N.Engl. J. Med. 2011, 365:1118-1127.
13. El-Serag H.B., Rudolph K.L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132:2557-2576.
14. Esteller M. Epigenetics in cancer. N.Engl. J. Med. 2008, 358:1148-1159.
15. Finn O.J. Cancer immunology. N.Engl. J. Med. 2008, 358:2704-2715.
16. Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell 2010, 140:883-899.
17. Herzer K., Hofmann T.G., Teufel A., Schimanski C.C., Moehler M., Kanzler S., Schulze-Bergkamen H., Galle P.R. IFN-α-induced apoptosis in hepatocellular carcinoma involves promyelocytic leukemia protein and TRAIL independently of p53. Cancer Res. 2009, 69:855-862.
18. Hoshida Y., Villanueva A., Kobayashi M., Peix J., Chiang D.Y., Camargo A., Gupta S., Moore J., Wrobel M.J., Lerner J., et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N.Engl. J. Med. 2008, 359:1995-2004.
19. Hoshida Y., Toffanin S., Lachenmayer A., Villanueva A., Minguez B., Llovet J.M. Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin. Liver Dis. 2010, 30:35-51.
20. Hou J., Wang P., Lin L., Liu X., Ma F., An H., Wang Z., Cao X. MicroRNA-146a feedback inhibits RIG-I-dependent type I IFN production in macrophages by targeting TRAF6, IRAK1, and IRAK2. J.Immunol. 2009, 183:2150-2158.
21. Hou J., Lin L., Zhou W., Wang Z., Ding G., Dong Q., Qin L., Wu X., Zheng Y., Yang Y., et al. Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell 2011, 19:232-243.
22. Ji J., Shi J., Budhu A., Yu Z., Forgues M., Roessler S., Ambs S., Chen Y., Meltzer P.S., Croce C.M., et al. MicroRNA expression, survival, and response to interferon in liver cancer. N.Engl. J. Med. 2009, 361:1437-1447.
23. Jiang F., Ramanathan A., Miller M.T., Tang G.Q., Gale M., Patel S.S., Marcotrigiano J. Structural basis of RNA recognition and activation by innate immune receptor RIG-I. Nature 2011, 479:423-427.
24. Jiang L.J., Zhang N.N., Ding F., Li X.Y., Chen L., Zhang H.X., Zhang W., Chen S.J., Wang Z.G., Li J.M., et al. RA-inducible gene-I induction augments STAT1 activation to inhibit leukemia cell proliferation. Proc. Natl. Acad. Sci. USA 2011, 108:1897-1902.
25. Kowalinski E., Lunardi T., McCarthy A.A., Louber J., Brunel J., Grigorov B., Gerlier D., Cusack S. Structural basis for the activation of innate immune pattern-recognition receptor RIG-I by viral RNA. Cell 2011, 147:423-435.
26. Kübler K., Gehrke N., Riemann S., Böhnert V., Zillinger T., Hartmann E., Pölcher M., Rudlowski C., Kuhn W., Hartmann G., Barchet W. Targeted activation of RNA helicase retinoic acid-inducible gene-I induces proimmunogenic apoptosis of human ovarian cancer cells. Cancer Res. 2010, 70:5293-5304.
27. Llovet J.M., Burroughs A., Bruix J. Hepatocellular carcinoma. Lancet 2003, 362:1907-1917.
28. Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.F., de Oliveira A.C., Santoro A., Raoul J.L., Forner A., et al. Sorafenib in advanced hepatocellular carcinoma. N.Engl. J. Med. 2008, 359:378-390. SHARP Investigators Study Group.
29. Lo C.M., Liu C.L., Chan S.C., Lam C.M., Poon R.T., Ng I.O., Fan S.T., Wong J. A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann. Surg. 2007, 245:831-842.
30. Luo D., Ding S.C., Vela A., Kohlway A., Lindenbach B.D., Pyle A.M. Structural insights into RNA recognition by RIG-I. Cell 2011, 147:409-422.
31. Melief C.J. Cancer immunotherapy by dendritic cells. Immunity 2008, 29:372-383.
32. Mínguez B., Lachenmayer A. Diagnostic and prognostic molecular markers in hepatocellular carcinoma. Dis. Markers 2011, 31:181-190.
33. Naugler W.E., Sakurai T., Kim S., Maeda S., Kim K., Elsharkawy A.M., Karin M. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007, 317:121-124.
34. Ng I.O., Ng M.M., Lai E.C., Fan S.T. Better survival in female patients with hepatocellular carcinoma. Possible causes from a pathologic approach. Cancer 1995, 75:18-22.
35. Park E.J., Lee J.H., Yu G.Y., He G., Ali S.R., Holzer R.G., Osterreicher C.H., Takahashi H., Karin M. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 2010, 140:197-208.
36. Platanias L.C. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat. Rev. Immunol. 2005, 5:375-386.
37. Puhr M., Santer F.R., Neuwirt H., Susani M., Nemeth J.A., Hobisch A., Kenner L., Culig Z. Down-regulation of suppressor of cytokine signaling-3 causes prostate cancer cell death through activation of the extrinsic and intrinsic apoptosis pathways. Cancer Res. 2009, 69:7375-7384.
38. Ruggieri A., Barbati C., Malorni W. Cellular and molecular mechanisms involved in hepatocellular carcinoma gender disparity. Int. J. Cancer 2010, 127:499-504.
39. Shen Y.C., Hsu C., Chen L.T., Cheng C.C., Hu F.C., Cheng A.L. Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): a meta-regression approach. J.Hepatol. 2010, 52:889-894.
40. Shuai K., Liu B. Regulation of JAK-STAT signalling in the immune system. Nat. Rev. Immunol. 2003, 3:900-911.
41. Sun H.C., Tang Z.Y., Wang L., Qin L.X., Ma Z.C., Ye Q.H., Zhang B.H., Qian Y.B., Wu Z.Q., Fan J., et al. Postoperative interferon α treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J.Cancer Res. Clin. Oncol. 2006, 132:458-465.
42. Takeuchi O., Akira S. Pattern recognition receptors and inflammation. Cell 2010, 140:805-820.
43. Taniguchi T., Takaoka A. A weak signal for strong responses: interferon-α/β revisited. Nat. Rev. Mol. Cell Biol. 2001, 2:378-386.
44. Vana J., Murphy G.P., Aronoff B.L., Baker H.W. Primary liver tumors and oral contraceptives. Results of a survey. JAMA 1977, 238:2154-2158.
45. Wang L., Tang Z.Y., Qin L.X., Wu X.F., Sun H.C., Xue Q., Ye S.L. High-dose and long-term therapy with interferon-α inhibits tumor growth and recurrence in nude mice bearing human hepatocellular carcinoma xenografts with high metastatic potential. Hepatology 2000, 32:43-48.
46. -/- mice develop colitis associated with downregulation of Gαi2. Cell Res. 2007, 17:858-868.
47. Zhang N.N., Shen S.H., Jiang L.J., Zhang W., Zhang H.X., Sun Y.P., Li X.Y., Huang Q.H., Ge B.X., Chen S.J., et al. RIG-I plays a critical role in negatively regulating granulocytic proliferation. Proc. Natl. Acad. Sci. USA 2008, 105:10553-10558.
48. Zhu Z.Z., Di J.Z., Gu W.Y., Cong W.M., Gawron A., Wang Y., Zheng Q., Wang A.Z., Zhu G., Zhang P., Hou L. Association of genetic polymorphisms in STAT1 gene with increased risk of hepatocellular carcinoma. Oncology 2010, 78:382-388.
49. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 2005, 5:263-274.